scholarly journals In vitro activity of the tribactam GV104326 against gram-positive, gram-negative, and anaerobic bacteria.

1994 ◽  
Vol 38 (10) ◽  
pp. 2362-2368 ◽  
Author(s):  
E Di Modugno ◽  
I Erbetti ◽  
L Ferrari ◽  
G Galassi ◽  
S M Hammond ◽  
...  
2006 ◽  
Vol 50 (6) ◽  
pp. 2261-2264 ◽  
Author(s):  
Hee-Soo Park ◽  
Hyun-Joo Kim ◽  
Min-Jung Seol ◽  
Dong-Rack Choi ◽  
Eung-Chil Choi ◽  
...  

ABSTRACT DW-224a showed the most potent in vitro activity among the quinolone compounds tested against clinical isolates of gram-positive bacteria. Against gram-negative bacteria, DW-224a was slightly less active than the other fluoroquinolones. The in vivo activities of DW-224a against gram-positive bacteria were more potent than those of other quinolones.


Author(s):  
Meredith A. Hackel ◽  
James A. Karlowsky ◽  
Michele A. Canino ◽  
Daniel F. Sahm ◽  
Nicole E. Scangarella-Oman

Gepotidacin (formerly GSK2140944) is a first in class triazaacenaphthylene antibacterial currently in Phase III clinical trials. When tested against Gram-negative ( n =333) and Gram-positive ( n =225) anaerobes by agar dilution, gepotidacin inhibited 90% of isolates (MIC 90 ) at concentrations of 4 and 2 μg/ml, respectively. Given gepotidacin’s in vitro activity against the anaerobic isolates tested, further study is warranted to better understand gepotidacin’s utility in the treatment of infections caused by clinically relevant anaerobic organisms.


2010 ◽  
Vol 25 (1) ◽  
Author(s):  
Elisabetta Maioli ◽  
Erika Coppo ◽  
Ramona Barbieri ◽  
Elisabetta Canepa ◽  
Laura Gualco ◽  
...  

Chemotherapy ◽  
2007 ◽  
Vol 54 (1) ◽  
pp. 43-49 ◽  
Author(s):  
S. Roveta ◽  
A. Marchese ◽  
E.A. Debbia

Chemotherapy ◽  
1997 ◽  
Vol 43 (6) ◽  
pp. 393-399 ◽  
Author(s):  
Giovanni Bonfiglio ◽  
Giuseppa Maccarone ◽  
Maria Lina Mezzatesta ◽  
Angela Privitera ◽  
Vincenzo Carciotto ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document